Action to Cure Kidney Cancer Secures Continuation of $10 Million for Kidney Cancer Research
Action to Cure Kidney Cancer was instrumental in securing the continuation of kidney cancer’s $10 million funding for fiscal year 2018, which commenced on September 1, 2017. In March 2017, the Consolidated Appropriations Act for fiscal year 2017, which called for a $10 million appropriation for kidney cancer research as part of the Congressionally Directed Medical Research Programs, managed by the Department of Defense, was signed by the President. Kidney cancer joined a group of only five cancers that have received such targeted funding: breast, prostate, ovarian, and lung.
James Brugarolas, MD, PhD, Head of the Kidney Cancer Program at The University of Texas Southwestern, said, “This $10 million appropriation represents a landmark commitment by the federal government to invest in kidney cancer research and seek a cure for this disease.”
Action to Cure Kidney Cancer has been advocating for 13 years for increased funding for kidney cancer research. The following legislators gave critical support in obtaining the research funding: Rep. Peter King (R–NY), Rep. Jared Polis (D–CO), Sen. Charles Schumer (D–NY), Sen. Kirsten Gillibrand (D–NY), former Congressman Steve Israel (D–NY), and Rep. Nita Lowey (D–NY).